RPH-2823 is a triamterene derivative that inhibits transepithelial Na⁺ transport by interacting with the Na⁺ channel or a regulatory site within the apical membrane, leading to a dose-dependent reduction in short-circuit current (SCC) and an increase in transepithelial resistance; it can prevent furosemide-induced kaliuresis in vivo.